Javascript must be enabled to continue!
A randomized control trial of re-designed and shorter research informed consent forms to improve comprehension
View through CrossRef
Background/Aims:
Informed consent forms are an essential component of ethical clinical research. However, they are failing. They are long, legalistic, and written at an 11th-grade reading level. Consequently, many participants have poor comprehension of the research they are considering. Our objective is to assess participant comprehension and satisfaction across three informed consent forms of different lengths and formats including one based on the Food and Drug Administration’s (FDA) 2024 draft summary template.
Methods:
In total, 334 healthy participants from AmeriSpeak’s online survey panel were recruited via email and AmeriSpeak’s member portal, oversampling less educated individuals and those from racial and ethnic minority groups. Participants were randomized to three informed consent forms—long, medium, and short—and were asked to imagine hypothetically being a patient considering joining a study. They were given a brief introduction on the purpose of informed consent forms and of this project’s goal to evaluate comprehension, satisfaction, and willingness to join the described hypothetical study but were not told the hypothesis or that there were three different informed consent forms. The long informed consent form (21 pages) was used in an actual international Bristol Myers Squibb study concerning a stroke prevention regimen. The long informed consent form contained longer paragraphs and lists and was written just below an 11th-grade level. The long informed consent form was modified to create the medium (14 pages) and short informed consent forms (3 pages), which both used simpler words, shorter sentences, less passive voice, tables, and other patient-friendly edits to achieve below sixth-grade reading levels. The short informed consent form was adapted from the Food and Drug Administration’s 2024 draft summary template.
Results:
The medium informed consent form (mean score of 79.3%) scored significantly higher on comprehension than the long informed consent form (65.7% mean score, p < 0.001) or the short informed consent form (69.3% mean score, p = 0.006). Compared to the long informed consent form, fewer medium informed consent form participants found their informed consent form “too long” or “too detailed.” Compared to the long and medium informed consent forms, more short informed consent form participants reported wanting more information on study procedures.
Conclusion:
The medium-length informed consent form, written at a sixth-grade reading level, with shorter words and sentences, tables, and enhanced formatting, produced significantly better comprehension than longer or shorter informed consent forms. The short informed consent form produced the same level of comprehension as a long informed consent form used in approved clinical trials. Researchers, pharmaceutical companies, and institutional review boards should adopt these informed consent form modifications to increase participant comprehension and satisfaction.
SAGE Publications
Title: A randomized control trial of re-designed and shorter research informed consent forms to improve comprehension
Description:
Background/Aims:
Informed consent forms are an essential component of ethical clinical research.
However, they are failing.
They are long, legalistic, and written at an 11th-grade reading level.
Consequently, many participants have poor comprehension of the research they are considering.
Our objective is to assess participant comprehension and satisfaction across three informed consent forms of different lengths and formats including one based on the Food and Drug Administration’s (FDA) 2024 draft summary template.
Methods:
In total, 334 healthy participants from AmeriSpeak’s online survey panel were recruited via email and AmeriSpeak’s member portal, oversampling less educated individuals and those from racial and ethnic minority groups.
Participants were randomized to three informed consent forms—long, medium, and short—and were asked to imagine hypothetically being a patient considering joining a study.
They were given a brief introduction on the purpose of informed consent forms and of this project’s goal to evaluate comprehension, satisfaction, and willingness to join the described hypothetical study but were not told the hypothesis or that there were three different informed consent forms.
The long informed consent form (21 pages) was used in an actual international Bristol Myers Squibb study concerning a stroke prevention regimen.
The long informed consent form contained longer paragraphs and lists and was written just below an 11th-grade level.
The long informed consent form was modified to create the medium (14 pages) and short informed consent forms (3 pages), which both used simpler words, shorter sentences, less passive voice, tables, and other patient-friendly edits to achieve below sixth-grade reading levels.
The short informed consent form was adapted from the Food and Drug Administration’s 2024 draft summary template.
Results:
The medium informed consent form (mean score of 79.
3%) scored significantly higher on comprehension than the long informed consent form (65.
7% mean score, p < 0.
001) or the short informed consent form (69.
3% mean score, p = 0.
006).
Compared to the long informed consent form, fewer medium informed consent form participants found their informed consent form “too long” or “too detailed.
” Compared to the long and medium informed consent forms, more short informed consent form participants reported wanting more information on study procedures.
Conclusion:
The medium-length informed consent form, written at a sixth-grade reading level, with shorter words and sentences, tables, and enhanced formatting, produced significantly better comprehension than longer or shorter informed consent forms.
The short informed consent form produced the same level of comprehension as a long informed consent form used in approved clinical trials.
Researchers, pharmaceutical companies, and institutional review boards should adopt these informed consent form modifications to increase participant comprehension and satisfaction.
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Analisis Fenomena Informed Consent: Tantangan dan Anomali bagi Dokter Muda di Jawa Timur
Analisis Fenomena Informed Consent: Tantangan dan Anomali bagi Dokter Muda di Jawa Timur
ABSTRACT Clerkship who are studying at Network Hospital often deal directly with patients. Clerkships also learn to convey informed consent, which will determine the patient's will...
EVALUASI KETIDAKLENGKAPAN PENGISIAN INFORMED CONSENT TINDAKAN OPERASI DI RUMAH SAKIT MUHAMMADIYAH LAMONGAN
EVALUASI KETIDAKLENGKAPAN PENGISIAN INFORMED CONSENT TINDAKAN OPERASI DI RUMAH SAKIT MUHAMMADIYAH LAMONGAN
Latar belakang: informed consent adalah persetujuan tindakan medis yang diberikan kepada pasien atau keluarga terdekatnya setelah mendapat penjelasan lengkap tentang tindakan medis...
Transfer between listening comprehension and reading comprehension in English
Transfer between listening comprehension and reading comprehension in English
Purposes The purposes of this research were to find out if there was any transfer between listening comprehension and reading comprehension in English ; and to find out if there w...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...

